TROG 02.03 - BLADDER (Phase III) - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

Primary Sponsor

Urological Society of Australasia

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Dr Kumar Gogna, QRI Mater Centre, QLD

Trial Contact

Kumar Gogna

Clinical Trial Registration

Registration Link

Prof Paul Keall, Image X Director and VITaL trial chief investigator

15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

TROG 03.01 – Oesophagus

TROG 11.A – ANROTAT

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative